Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG

Elanco Animal Health  said on Tuesday it would buy Bayer's  veterinary drugs unit in a cash and stock deal valued at $7.6 billion, creating the second largest animal health business and expanding Elanco's reach in the pet e-commerce space.

Elanco to buy Bayer's animal health unit for $7.6 billion

Elanco Animal Health ELAN, +1.53% said it's buying Bayer's BAYN, -0.77% animal health business for $7.6 billion.

Elanco buying Bayer's animal health business for $7.6 billion

The animal health company's top and bottom lines improved considerably in Q2. But its full-year guidance reflected worries about some market dynamics.

Elanco Animal Health Beats Q2 Earnings Estimates but Faces Increasing Headwinds

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q2 2019 Results - Earnings Call Transcript

Elanco Animal Health stock popped Tuesday on investor relief the second-quarter earnings beat didn't come alongside an expected acquisition by Bayer. Elanco stock had been under pressure.

No Deal: Pharma Stock Rebounds After 10% Dive On Rumored Buyout

Shares of Elanco Animal Health Inc. ELAN, +2.86% surged 1.5% in morning trading Tuesday, putting them on track to snap a four-day losing streak, after the animal health company reported better-than-expected second-quarter earnings, but trimmed the top end of its full-year revenue guidance range, citing an increased headwind from African Swine Fever and the expected disruption of certain injectable cattle products.

Elanco Animal Health's stock surges toward snapping losing streak after profit, revenue beat expectations

Elanco Animal Health (NYSE: ELAN) reported adjusted second-quarter earnings of 28 cents per share, which beat the analyst consensus estimate of 26 cents by 7.69%.

Elanco Animal Health Reports Mixed Q2 Earnings

Bayer and Elanco Reportedly in Early Merger Talks; Deal Worth over $6.0 Billion. Spin-Off Research, founded by Joe Cornell, has tracked and provided analysis on Spin-Offs since 1997.

Elanco Animal Health And Bayer In Early Talks To Combine Animal Health Units

The two companies are working with banks to ensure any merger would secure regulatory approval.

German pharmaceutical company Bayer seeks animal health merger with Elanco

Bayer  has approached U.S. drug firm Elanco Animal Health  to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

Dell Technologies

Eventbrite

Lyft

Tencent Music Entertainment Group 

A parade of tech companies has stepped onto public markets in the past year, and their stocks have taken off.

5 IPOs Top Investors Are Buying

Elanco Animal Health Incorporated (ELAN) CEO Jeffrey Simmons on Q1 2019 Results - Earnings Call Transcript

Aratana Therapeutics

Elanco Animal Health Inc. announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc.

Elanco Animal Health Announces $245M Stock-For-Stock Acquisition Of Aratana Therapeutics

Shares of Aratana Therapeutics shot up 39% in premarket trade on Friday after Elanco Animal Health announced it would be acquiring the pet therapeutics company in a deal worth up to $245 million.

Animal health giant Elanco to acquire Aratana Therapeutics

Elanco Animal Health Inc (NYSE: ELAN), a global animal health company, began trading Monday as a fully standalone entity after completing a split from Eli Lilly And Co

News for Elanco Animal Health Inc Stock (ELAN)